Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Cerebral Palsy Clinical Trial

Official title:

A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00491894
• Other study ID #: Sc-GLYCO-06-01
• Status: Completed
• Phase: Phase 3
• First received: June 22, 2007
• Last updated: June 5, 2012
• Start date: March 2007
• Est. completion date: June 2008

Study information

• Verified date: April 2012
• Source: Shionogi Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is an open-label clinical research study of an oral glycopyrrolate liquid for the treatment of chronic moderate to severe drooling in patients with cerebral palsy or other neurological conditions. Patients participating in the study will receive oral glycopyrrolate liquid (1 mg/5 ml) three times a day (TID) for study duration of 24 weeks. After a washout, screening, and 2-day baseline period, patients will be enrolled in a 4-week dose titration period. Glycopyrrolate liquid doses will be titrated using dose levels in the Dose Titration Schedule. Titration will begin at 0.02 mg/kg per dose TID and sequentially increased in 0.02 mg/kg per dose increments TID every 5-7 days during the first four weeks until optimal individualized response is obtained for each patient or a maximum dose of 0.1 mg/kg TID is reached, not exceeding 3 mg TID or Dose-level 5 in the Dose Titration Schedule, whichever is lesser. Optimal dose for each patient is the dose at which he/she is receiving the maximum benefit from the study drug (greatest improvement in drooling) while experiencing minimum side effects. All patients will receive close attention by study staff throughout the study.

Other known NCT identifiers

• NCT00425087

Recruitment information / eligibility

• Status: Completed
• Enrollment: 137
• Est. completion date: June 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years to 18 Years

Eligibility

Inclusion Criteria:

To be included in this study, patients must meet the following criteria:

• Male or female, weighing at least 13 kilograms (27 pounds), aged 3 through 18 years

• Diagnosis of cerebral palsy and/or mental retardation or any other neurologic impairment or condition (cognitively capable and cognitively impaired patients may be enrolled)

• Chronic drooling in the absence of treatment to the extent that the chin or clothing becomes wet on most days by confirming the Modified Teacher's Drooling Scale score = 5

• Must be living in a situation where reliable parents/caregivers are willing and capable of administering medications, as determined by the investigator

• Written informed consent signed by the parent or legally acceptable representative

• Written assent signed by the age-appropriate patient if mentally capable, as determined by the investigator, and required by the site's Institutional Review Board

• If female of childbearing potential, the patient must have a negative pregnancy test at screening and Visit 2

• If female of childbearing potential and sexually active, she must use a medically acceptable form of contraception

Exclusion Criteria:

Patients are excluded from this study if they meet any of the following criteria:

• Patients who used glycopyrrolate within approximately 24 hours prior to the start of the baseline period, which began on Day -2

• Patients who used prohibited medications within 5 plasma half-lives of the medication prior to the start of the baseline period

• Patients injected with intrasalivary gland botulinum toxin within 10 months prior to the start of the baseline period

• Patients using intraoral devices or prosthetics for the treatment of drooling within 1 week prior to the start of the baseline period

• Patients receiving acupuncture for the treatment of drooling or who have received acupuncture for the treatment of drooling within 3 months prior to the start of the baseline period

• Patients who have medical conditions contraindicating anticholinergic therapy including gastrointestinal reflux, narrow-angle glaucoma, obstructive uropathy, obstructive disease of the gastrointestinal tract (i.e., delayed gastric emptying, pyloroduodenal stenosis, etc.), paralytic ileus, intestinal atony, vesicoureteral reflux, reactive airway disease, myasthenia gravis, hyperthyroidism, cardiac arrhythmias and/or tachycardia, and/or clinically significant electrocardiogram abnormalities, as determined by the investigator

• Patients who have a known contraindication to the study medication, including allergy to the study medication or any of its components

• Patients who have poorly controlled seizures defined as daily seizures

• Patients who have a history of obstructive disease of the gastrointestinal tract (i.e., intestinal obstruction)

• Patients who have clinically significant hepatic or renal impairment, at the discretion of the investigator

• Patients who are pregnant or breastfeeding

• Patients who have received any investigational drugs within 30 days of study entry

• Patient, families, or parents/caregivers who are expected to be non-compliant with the study procedures, as judged by the investigator

• Patients who are unable to meet the requirements of the study for any reason, as determined by the investigator

• Patients who have unstable mental disease, as determined by the investigator

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cerebral Palsy
• Disease
• Intellectual Disability
• Mental Retardation
• Neurological Conditions
• Sialorrhea

Intervention

Drug:
• Oral Glycopyrrolate Liquid
Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver

Locations

Country	Name	City	State
United States	Akron's Childrens	Akron	Ohio
United States	Child Neurology Associates, PC	Atlanta	Georgia
United States	St. Mary's for Children	Bayside	New York
United States	The Children's Center	Bethany	Oklahoma
United States	Rocky Mountain Pediatrics	Lakewood	Colorado
United States	Hattie Larltham Center for Children with Disabilities	Mantua	Ohio
United States	Alamo City Clinical Research	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Shionogi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS)	The primary efficacy variable was patient's response status using the change from baseline to Week 24 evaluations of the mTDS assessment. Each patient was classified as a responder or non-responder according to the change in their mean mTDS rating from baseline to Week 24. Responders were patients who had at least a 3-point decrease in mTDS rating from baseline	6 months	No
Secondary	Parent/Caregiver's Assessment of the Extent of Drooling Using Visual Analog Scale (VAS)	Parents/caregivers were to complete a 10 cm "Parent/Caregiver's Assessment of Extent of Drooling for the Day" VAS assessment (0 = normal; 10 = extremely wet) to provide an overall assessment of the extent of drooling for that day.	Baseline	No
Secondary	Parent/Caregiver's Assessment of the Extent of Drooling Using VAS	Parents/caregivers were to complete a 10 cm "Parent/Caregiver's Assessment of Extent of Drooling for the Day" VAS assessment (0 = normal; 10 = extremely wet) to provide an overall assessment of the extent of drooling for that day.	Week 24	No
Secondary	Parent/Caregiver's Global Assessment of Treatment	The parent/caregiver performed an overall evaluation of glycopyrrolate liquid for the treatment of drooling, benefits, and side effects over the duration of the study. The parent/caregiver selected one of the following choices to assess if 'This is a worthwhile treatment': 1 = strongly agree, 2 = agree, 3 = neutral, 4 = disagree, 5 = strongly disagree. A dichotomous global assessment was also performed and summarized with the categories 'responder' (strongly agree and agree responses aggregated) and 'non-responder'(neutral, disagree, and strongly disagree responses aggregated)	Week 24	No
Secondary	Investigator's Global Assessment of Treatment	The investigator performed an overall evaluation of glycopyrrolate liquid for the treatment of drooling, benefits, and side effects over the duration of the study. The investigator selected one of the following choices to assess if 'This is a worthwhile treatment': 1 = strongly agree, 2 = agree, 3 = neutral, 4 = disagree, 5 = strongly disagree. A dichotomous global assessment was also performed and summarized with the categories 'responder' (strongly agree and agree responses aggregated) and 'non-responder' (neutral, disagree, and strongly disagree responses aggregated)	Week 24	No